Company intelligence / Profile preview

Maxwell Software

Austin, Texas, United Statesmaxwellapps.com ↗

Ownership: Private
Development stage: Commercial

Overview

Maxwell Biosciences is a preclinical-stage biotechnology platform company developing synthetic immune system therapeutics that mimic and improve upon natural human peptides. Its lead program targets broad-spectrum infectious agents—including AMR bacteria and major viral pathogens—using shelf-stable compounds that do not require cold-chain storage. The nasal spray candidate has completed animal studies with NIAID sponsorship and will enter human trials soon. Data from multiple academic collaborations support potent activity against a wide range of pathogens.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Maxwell Software.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxwell Software.

Explore the full profile